| Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a … JA Dormandy, B Charbonnel, DJA Eckland, E Erdmann, ... The Lancet 366 (9493), 1279-1289, 2005 | 5038 | 2005 |
| 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD F Cosentino, L David European heart journal 41 (2), 255-323, 2020 | 3456 | 2020 |
| ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular … Authors/Task Force Members, L Rydén, PJ Grant, SD Anker, C Berne, ... European heart journal 34 (39), 3035-3087, 2013 | 2271 | 2013 |
| Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study LF Van Gaal, AM Rissanen, AJ Scheen, O Ziegler, S Rössner The Lancet 365 (9468), 1389-1397, 2005 | 2014 | 2005 |
| Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes N Esser, S Legrand-Poels, J Piette, AJ Scheen, N Paquot Diabetes research and clinical practice 105 (2), 141-150, 2014 | 1919 | 2014 |
| Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial AF Hernandez, JB Green, S Janmohamed, RB D'Agostino, CB Granger, ... The Lancet 392 (10157), 1519-1529, 2018 | 1122 | 2018 |
| Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study AJ Scheen, N Finer, P Hollander, MD Jensen, LF Van Gaal The Lancet 368 (9548), 1660-1672, 2006 | 977 | 2006 |
| Clinical pharmacokinetics of metformin AJ Scheen Clinical pharmacokinetics 30, 359-371, 1996 | 752 | 1996 |
| Roles of circadian rhythmicity and sleep in human glucose regulation E Van Cauter, KS Polonsky, AJ Scheen Endocrine reviews 18 (5), 716-738, 1997 | 683 | 1997 |
| Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty FH Luyckx, C Desaive, A Thiry, W Dewe, AJ Scheen, JE Gielen, ... International journal of obesity 22 (3), 222-226, 1998 | 620 | 1998 |
| 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial CW Le Roux, A Astrup, K Fujioka, F Greenway, DCW Lau, L Van Gaal, ... The Lancet 389 (10077), 1399-1409, 2017 | 608 | 2017 |
| Effect of nateglinide on the incidence of diabetes and cardiovascular events NAVIGATOR Study Group New England Journal of Medicine 362 (16), 1463-1476, 2010 | 560 | 2010 |
| Pharmacodynamics, efficacy and safety of sodium–glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus AJ Scheen Drugs 75, 33-59, 2015 | 530 | 2015 |
| Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication MA De Hert, R van Winkel, D Van Eyck, L Hanssens, M Wampers, ... Schizophrenia research 83 (1), 87-93, 2006 | 481 | 2006 |
| Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss FH Luyckx, PJ Lefebvre, AJ Scheen Diabetes and Metabolism 26 (2), 98-106, 2000 | 470 | 2000 |
| Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system AJ Scheen Drugs 64, 2537-2565, 2004 | 421 | 2004 |
| Pathophysiology of type 2 diabetes AJ Scheen Acta Clinica Belgica 58 (6), 335-341, 2003 | 414 | 2003 |
| Magnesium and glucose homeostasis G Paolisso, A Scheen, F d'Onofrio, P Lefebvre Diabetologia 33, 511-514, 1990 | 399 | 1990 |
| Renin-angiotensin system inhibition prevents type 2 diabetes mellitus: part 1. A meta-analysis of randomised clinical trials AJ Scheen Diabetes & metabolism 30 (6), 487-496, 2004 | 398 | 2004 |
| Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective … M De Hert, V Schreurs, K Sweers, D Van Eyck, L Hanssens, S Šinko, ... Schizophrenia research 101 (1-3), 295-303, 2008 | 384 | 2008 |
